Dual inhibition of CDK4/6 and MEK demonstrated synergistic antitumor activity in patient-derived xenografts (PDX) and de novo tumors in immunocompetent mouse models of MPNST. Here, CDK4 is linked to malignant peripheral nerve sheath tumor.